Janux TherapeuticsJANX +0.46%46 Current Ratio is 17.01 as of Mar. 2026, which is 42% below its 10-year median of 29.14. GuruFocus rates JANX with a GF Score™ of 46/100 and a GF Value™ of $39.67 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, Janux Therapeutics ranks better than 89.16% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Janux Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 17.01.
Janux Therapeutics has a current ratio of 17.01. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Janux Therapeutics's Current Ratio or its related term are showing as below:
JANX'
s Current Ratio Range Over the Past 10 Years
Min: 0.14 Med: 29.14 Max: 62.09
Current: 17.01
During the past 7 years, Janux Therapeutics's highest Current Ratio was 62.09. The lowest was 0.14. And the median was 29.14.
JANX's Current Ratio is ranked better than 89.16% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs JANX: 17.01
Janux Therapeutics (NAS:JANX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Janux Therapeutics Current Ratio Related Terms
Janux Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Janux Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JANX vs SLDB, TBPH, MRVI: Current Ratio Comparison
For the Biotechnology subindustry, Janux Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Janux Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Janux Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Janux Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Janux Therapeutics (JANX) has a Current Ratio of 17.01 as of Mar. 2026. This is 42% below median its historical median of 29.14. Over the past decade, Janux Therapeutics' Current Ratio has ranged from 0.14 to 62.09. According to the industry distribution chart, Janux Therapeutics ranks #153 out of 1412 companies in the Biotechnology industry, placing it in the top 10.8%.
Is Janux Therapeutics' Current Ratio too high?
Janux Therapeutics' current Current Ratio of 17.01 is 42% below median its 10-year median of 29.14. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 62.09. The Biotechnology industry median Current Ratio is 3.90. Janux Therapeutics' value of 17.01 is 336.2% above this industry median. Based on the distribution chart, Janux Therapeutics ranks #153 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Janux Therapeutics has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Janux Therapeutics' Current Ratio compare to SLDB and TBPH?
According to the Biotechnology industry distribution chart, Janux Therapeutics ranks #153 out of 1412 companies for Current Ratio. This places Janux Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.90. Janux Therapeutics' value of 17.01 is 336.2% above this benchmark. Historically, Janux Therapeutics' own Current Ratio has ranged from 0.14 to 62.09 over the past decade. While the company's 10-year median is 29.14 vs. the industry median of 3.90, Janux Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Janux Therapeutics's current Current Ratio of 17.01 is 336.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Janux Therapeutics's current Current Ratio is 17.01, which is 42% below median its own 10-year median of 29.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Janux Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Janux Therapeutics (JANX) is currently considered Possible Value Trap. The stock's GF Value™ is $39.67, compared to a current price of $15.43 — trading 61.1% below its estimated fair value. The current Current Ratio is 17.01, which is 42% below median its 10-year median of 29.14 and 336.2% above the Biotechnology industry median of 3.90. Janux Therapeutics' overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Janux Therapeutics (JANX), the current Current Ratio is 17.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Janux Therapeutics (JANX) Overvalued in 2026?
Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued.
The current stock price of $15.43 is trading 61.1% below its estimated GF Value™ of $39.67.
GuruFocus considers Janux Therapeutics to be Possible Value Trap.
Key valuation signals for JANX:
Current Ratio: 17.01 (42% below median its 10-year median of 29.14)
GF Value™: $39.67 vs. price of $15.43 (61.1% below fair value)
Industry Position: 336.2% above the Biotechnology median (#153 of 1412)
No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
46GF Score
Get the complete analysis for JANX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JANX has been successfully added to your 
